Barbital

Summary

Barbital (CHEMBL444) is an approved small molecule (ATC N05CA04).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CA04
• Chemistry: 184.19 Da · C8H12N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL444
Name	Barbital
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2294
ChEBI	CHEBI:31252
ATC	N05CA04
Molecular formula	C8H12N2O3
Molecular weight	184.19
InChIKey	FTOAOBMCPZCFFF-UHFFFAOYSA-N

SMILES: CCC1(C(=O)NC(=O)NC1=O)CC

IUPAC name: 5,5-diethyl-1,3-diazinane-2,4,6-trione

ChEBI definition: A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by two ethyl groups. Formerly used as a hypnotic (sleeping aid).

Pharmacological roles (ChEBI): drug allergen.

Also known as: Barbital, NSC-31352, SID29215357, SID170465829, BARBITAL

Parent form; salt/anhydrous children: CHEMBL2105904

Patent coverage: 5,753 distinct patent families (15,317 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 15,266 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prelamin-A/C.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).